NZ210501A
(en)
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
US4703008A
(en)
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
KR850004274A
(ko)
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
US5856298A
(en)
|
1989-10-13 |
1999-01-05 |
Amgen Inc. |
Erythropoietin isoforms
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
WO1991005867A1
(fr)
|
1989-10-13 |
1991-05-02 |
Amgen Inc. |
Isoformes d'erythropoietine
|
IL110669A
(en)
|
1993-08-17 |
2008-11-26 |
Kirin Amgen Inc |
Erythropoietin analogs
|
US6562596B1
(en)
|
1993-10-06 |
2003-05-13 |
Amgen Inc. |
Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
|
US5830851A
(en)
|
1993-11-19 |
1998-11-03 |
Affymax Technologies N.V. |
Methods of administering peptides that bind to the erythropoietin receptor
|
US5773569A
(en)
|
1993-11-19 |
1998-06-30 |
Affymax Technologies N.V. |
Compounds and peptides that bind to the erythropoietin receptor
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
DE69534530T2
(de)
|
1994-08-12 |
2006-07-06 |
Immunomedics, Inc. |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US5767078A
(en)
|
1995-06-07 |
1998-06-16 |
Johnson; Dana L. |
Agonist peptide dimers
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
PT986644E
(pt)
|
1997-07-23 |
2007-01-31 |
Roche Diagnostics Gmbh |
Preparação de eritropoietina por activação genética endógena com promotores virais
|
US6030086A
(en)
|
1998-03-02 |
2000-02-29 |
Becton, Dickinson And Company |
Flash tube reflector with arc guide
|
US6310078B1
(en)
|
1998-04-20 |
2001-10-30 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted amino acids as erythropoietin mimetics
|
US20050181482A1
(en)
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
WO1999066054A2
(fr)
|
1998-06-15 |
1999-12-23 |
Genzyme Transgenics Corp. |
Fusion analogue d'erythropoietine-albumine serique humaine
|
HU228582B1
(en)
|
1998-10-23 |
2013-04-29 |
Kirin Amgen Inc |
Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
|
PT1813624E
(pt)
|
1998-10-23 |
2010-10-27 |
Amgen Inc |
Métodos e composições para a prevenção e tratamento da anemia
|
NZ512122A
(en)
|
1998-11-27 |
2003-12-19 |
Darwin Discovery Ltd |
Compositions and methods for increasing bone mineralization
|
EP1006184A1
(fr)
|
1998-12-03 |
2000-06-07 |
F. Hoffmann-La Roche Ag |
Protéines interagissant avec le récepteur de IGF-1, gènes codant pour ces protéines et leurs utilisations
|
EP1169352A4
(fr)
|
1999-04-14 |
2005-05-04 |
Smithkline Beecham Corp |
Anticorps du recepteur d'erythropoietine
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
JP2003512840A
(ja)
|
1999-10-22 |
2003-04-08 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
ラット脳に由来する核酸分子およびプログラム細胞死モデル
|
US20050202538A1
(en)
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
AU2695101A
(en)
|
2000-01-21 |
2001-07-31 |
Biovex Ltd |
Virus strains
|
AUPQ599700A0
(en)
|
2000-03-03 |
2000-03-23 |
Super Internet Site System Pty Ltd |
On-line geographical directory
|
US6586398B1
(en)
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
WO2001081405A2
(fr)
|
2000-04-21 |
2001-11-01 |
Amgen Inc. |
Methodes et compositions destinees a la prevention et au traitement de l'anemie
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
US7078376B1
(en)
|
2000-08-11 |
2006-07-18 |
Baxter Healthcare S.A. |
Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
|
PL365671A1
(en)
|
2000-09-08 |
2005-01-10 |
Gryphon Therapeutics, Inc. |
Synthetic erythropoiesis stimulating proteins
|
US7271689B1
(en)
|
2000-11-22 |
2007-09-18 |
Fonar Corporation |
Magnet structure
|
WO2002049673A2
(fr)
|
2000-12-20 |
2002-06-27 |
F. Hoffmann-La Roche Ag |
Conjugues d'erythropoietine
|
PL228041B1
(pl)
|
2001-01-05 |
2018-02-28 |
Amgen Fremont Inc |
Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne.
|
IL158261A0
(en)
|
2001-04-04 |
2004-05-12 |
Genodyssee |
New polynucleotides and polypeptides of the erythropoietin gene
|
JP4516719B2
(ja)
|
2001-05-11 |
2010-08-04 |
アムジエン・インコーポレーテツド |
Tall−1と結合するペプチド及び関連分子
|
YU103003A
(sh)
|
2001-06-26 |
2006-05-25 |
Abgenix Inc. |
Antitela za opgl
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
ATE531390T1
(de)
|
2001-08-23 |
2011-11-15 |
Genmab As |
Interleukin-15-(il-15-)spezifische menschliche antikörper
|
US7247304B2
(en)
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
US6930086B2
(en)
|
2001-09-25 |
2005-08-16 |
Hoffmann-La Roche Inc. |
Diglycosylated erythropoietin
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
AU2002351746A1
(en)
|
2001-12-21 |
2003-07-15 |
Maxygen Aps |
Erythropoietin conjugates
|
ES2427964T3
(es)
|
2002-01-18 |
2013-11-05 |
Pierre Fabre Medicament |
Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
WO2003064664A1
(fr)
|
2002-01-31 |
2003-08-07 |
Oxford Biomedica (Uk) Limited |
Vecteur d'expression de l'erythropoietine physiologiquement regule, destine au traitement de l'anemie
|
GB0202252D0
(en)
|
2002-01-31 |
2002-03-20 |
Oxford Biomedica Ltd |
Anemia
|
AU2002247896A1
(en)
|
2002-03-26 |
2003-10-08 |
Lek Pharmaceutical And Chemical Company D.D. |
Process for the preparation of a desired erythropoietin glyco-isoform profile
|
EP1572079A4
(fr)
|
2002-03-29 |
2006-09-06 |
Centocor Inc |
Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
|
CN102212537B
(zh)
|
2002-03-29 |
2013-08-14 |
组合化学工业株式会社 |
编码乙酰乳酸合酶的基因
|
CA2485365A1
(fr)
|
2002-05-13 |
2003-11-20 |
Modigenetech Ltd. |
Erythropoietine comportant une extension ctp
|
KR101086533B1
(ko)
|
2002-05-24 |
2011-11-23 |
쉐링 코포레이션 |
중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
CA2490411A1
(fr)
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
|
EP1545608A4
(fr)
|
2002-06-28 |
2006-09-13 |
Centocor Inc |
Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
|
AU2003246486A1
(en)
|
2002-07-19 |
2004-02-09 |
Cangene Corporation |
Pegylated erythropoietic compounds
|
AU2003254950A1
(en)
|
2002-08-26 |
2004-03-11 |
Kirin Beer Kabushiki Kaisha |
Peptides and drugs containing the same
|
NZ538569A
(en)
|
2002-09-06 |
2009-02-28 |
Amgen Inc |
Therapeutic human anti-IL-1R1 monoclonal antibody
|
BR0314107A
(pt)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Método de produção de derivados de hidroxialquil amido
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
US20040071694A1
(en)
|
2002-10-14 |
2004-04-15 |
Devries Peter J. |
Erythropoietin receptor binding antibodies
|
US7396913B2
(en)
|
2002-10-14 |
2008-07-08 |
Abbott Laboratories |
Erythropoietin receptor binding antibodies
|
TWI320716B
(en)
|
2002-10-14 |
2010-02-21 |
Abbott Lab |
Erythropoietin receptor binding antibodies
|
US7335743B2
(en)
|
2002-10-16 |
2008-02-26 |
Amgen Inc. |
Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
|
US20040091961A1
(en)
|
2002-11-08 |
2004-05-13 |
Evans Glen A. |
Enhanced variants of erythropoietin and methods of use
|
SI1581649T1
(sl)
|
2002-12-20 |
2011-09-30 |
Amgen Inc |
Vezna sredstva, ki zavirajo miostatin
|
JP2007528201A
(ja)
|
2003-03-14 |
2007-10-11 |
ファルマシア・コーポレーション |
癌治療のためのigf−i受容体に対する抗体
|
CA2519113C
(fr)
|
2003-04-02 |
2012-06-05 |
F. Hoffmann-La Roche Ag |
Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
|
US7220410B2
(en)
|
2003-04-18 |
2007-05-22 |
Galaxy Biotech, Llc |
Monoclonal antibodies to hepatocyte growth factor
|
US7638605B2
(en)
|
2003-05-01 |
2009-12-29 |
ImClone, LLC |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
CN1820024B
(zh)
|
2003-05-12 |
2011-06-22 |
阿费麦克斯公司 |
新的聚(乙二醇)修饰的化合物及其用途
|
EA010099B1
(ru)
|
2003-05-12 |
2008-06-30 |
Афимакс, Инк. |
Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения
|
CA2525568C
(fr)
|
2003-05-12 |
2017-07-25 |
Affymax, Inc. |
Nouveaux peptides se fixant au recepteur de l'erythropoietine
|
US7074755B2
(en)
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
JP2007537986A
(ja)
|
2003-05-30 |
2007-12-27 |
セントカー・インコーポレーテツド |
トランスグルタミナーゼを用いる新規なエリトロポエチン複合体の形成
|
WO2005001136A1
(fr)
|
2003-06-04 |
2005-01-06 |
Irm Llc |
Methodes et compositions pour la modulation de l'expression de l'erythropoietine
|
DE602004005597T2
(de)
|
2003-07-08 |
2008-02-14 |
Novo Nordisk A/S |
Tragbares medikamentenabgabegerät mit einer eingekapselten nadel
|
US7579157B2
(en)
|
2003-07-10 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Antibody selection method against IGF-IR
|
GEP20196963B
(en)
|
2003-07-15 |
2019-04-10 |
Inc Amgen |
Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
|
MEP31408A
(en)
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
US20050019914A1
(en)
|
2003-07-24 |
2005-01-27 |
Aventis Pharma Deutschland Gmbh |
Perfusion process for producing erythropoietin
|
GB0317511D0
(en)
|
2003-07-25 |
2003-08-27 |
Biovex Ltd |
Viral vectors
|
JP2007512001A
(ja)
|
2003-08-28 |
2007-05-17 |
バイオレクシス ファーマシューティカル コーポレイション |
Epoミメティックペプチドおよび融合タンパク質
|
BRPI0409650A
(pt)
|
2003-09-09 |
2006-04-25 |
Warren Pharmaceuticals Inc |
métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
|
JP4767857B2
(ja)
|
2003-09-30 |
2011-09-07 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ベンゾイミダゾール化合物
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
GEP20104991B
(en)
|
2003-11-07 |
2010-05-25 |
Immunex Corp |
Antibodies that bind interleukin-4 receptor
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
US7405198B2
(en)
|
2003-11-24 |
2008-07-29 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
WO2005058967A2
(fr)
|
2003-12-16 |
2005-06-30 |
Pierre Fabre Medicament |
Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
|
EP1548031A1
(fr)
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Erythropoietin identique à la nature
|
JP2008504008A
(ja)
|
2003-12-31 |
2008-02-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改良された薬物動態を有するFc−エリスロポエチン融合タンパク質
|
WO2005065239A2
(fr)
|
2003-12-31 |
2005-07-21 |
Centocor, Inc. |
Nouvelles proteines recombinees avec thiol libre n-terminal
|
US7423139B2
(en)
|
2004-01-20 |
2008-09-09 |
Insight Biopharmaceuticals Ltd. |
High level expression of recombinant human erythropoietin having a modified 5′-UTR
|
WO2005070451A1
(fr)
|
2004-01-22 |
2005-08-04 |
Zafena Aktiebolag |
Composition pharmaceutique comprenant une erythropoietine non glycosylee
|
WO2005084711A1
(fr)
|
2004-03-02 |
2005-09-15 |
Chengdu Institute Of Biological Products |
Erythropoietine recombinante pegylee a activite in vivo
|
TW200603818A
(en)
|
2004-03-11 |
2006-02-01 |
Fresenius Kabi De Gmbh |
Conjugates of hydroxyethyl starch and erythropoietin
|
US20060002929A1
(en)
|
2004-03-23 |
2006-01-05 |
Khare Sanjay D |
Monoclonal antibodies
|
US20050227289A1
(en)
|
2004-04-09 |
2005-10-13 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
GB2413328A
(en)
|
2004-04-23 |
2005-10-26 |
Cambridge Antibody Tech |
Erythropoietin protein variants
|
DK1781697T3
(da)
|
2004-07-07 |
2009-07-06 |
Lundbeck & Co As H |
Nyt carbamyleret erythropoietinprotein samt fremstillingsmetode
|
FR2873699B1
(fr)
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
US20060073563A1
(en)
|
2004-09-02 |
2006-04-06 |
Xencor, Inc. |
Erythropoietin derivatives with altered immunogenicity
|
JP2008519589A
(ja)
|
2004-11-10 |
2008-06-12 |
アプラゲン ゲーエムベーハー |
造血を促進する分子
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
CA2589860A1
(fr)
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Anticorps anti-amyloide humanise
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
ES2452115T3
(es)
|
2005-06-17 |
2014-03-31 |
Imclone Llc |
Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
|
WO2007000328A1
(fr)
|
2005-06-27 |
2007-01-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
|
EP2388276A3
(fr)
|
2005-07-18 |
2013-11-27 |
Amgen, Inc |
Anticorps humains à neutralisation anti-B7RP1
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
GB0603683D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007136752A2
(fr)
|
2006-05-19 |
2007-11-29 |
Glycofi, Inc. |
Compositions d'érythropoïétine
|
US7455663B2
(en)
|
2006-08-23 |
2008-11-25 |
Medtronic Minimed, Inc. |
Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US20100040610A1
(en)
|
2006-11-07 |
2010-02-18 |
Ayesha Sitlani |
Antagonists of pcsk9
|
WO2008057458A2
(fr)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonistes de pcsk9
|
JP5588175B2
(ja)
|
2006-11-07 |
2014-09-10 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Pcsk9のアンタゴニスト
|
EP2083859A4
(fr)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
Antagonistes de pcsk9
|
EP2129690A1
(fr)
|
2006-12-14 |
2009-12-09 |
Schering Corporation |
Anticorps anti-tslp technique
|
AR066042A1
(es)
|
2007-04-13 |
2009-07-22 |
Novartis Ag |
Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
|
AU2008265128A1
(en)
|
2007-06-20 |
2008-12-24 |
Irm Llc |
Methods and compositions for treating allergic diseases
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US8598320B2
(en)
|
2007-10-26 |
2013-12-03 |
Merck Sharp & Dohme Corp. |
Anti-PCSK9 and methods for treating lipid and cholesterol disorders
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
WO2011037791A1
(fr)
|
2009-09-25 |
2011-03-31 |
Merck Sharp & Dohme Corp. |
Antagonistes de pcsk9
|
AU2010313381A1
(en)
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX1 and AX189 PCSK9 antagonists and variants
|
WO2011053783A2
(fr)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Antagonistes et variants ax213 et ax132 pcsk9
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
AU2011225716A1
(en)
|
2010-03-11 |
2012-09-27 |
Pfizer Inc. |
Antibodies with pH dependent antigen binding
|
KR20130118925A
(ko)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
항-pcsk9 항체 및 사용 방법
|
MX367075B
(es)
|
2011-01-28 |
2019-08-05 |
Sanofi Biotechnology |
Anticuerpos humanos frente a pcsk9 para su uso en metodos de tratamiento de grupos concretos de pacientes.
|
WO2012134588A1
(fr)
*
|
2011-02-09 |
2012-10-04 |
Becton, Dickinson And Company |
Dispositif de perfusion à insertion et rétraction automatique d'aiguille d'intubateur
|
WO2012109530A1
(fr)
|
2011-02-11 |
2012-08-16 |
Irm Llc |
Antagonistes de pcsk9
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
JP6424407B2
(ja)
*
|
2012-07-11 |
2018-11-21 |
ユーエヌエル ホールディングス エルエルシーUNL Holdings LLC |
薬剤送達ポンプ用ベント式流体経路を有する挿入機構
|
ES2875957T3
(es)
|
2012-12-20 |
2021-11-11 |
Amgen Inc |
Agonistas del receptor APJ y usos de los mismos
|
US20140274874A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
AP2015008729A0
(en)
|
2013-03-14 |
2015-09-30 |
Amgen Inc |
Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
AU2016219391B2
(en)
|
2015-02-10 |
2020-05-21 |
Amgen Inc. |
Rotationally biased insertion mechanism for a drug delivery pump
|
JOP20170042B1
(ar)
|
2016-02-12 |
2022-09-15 |
Amgen Inc |
وسيلة توصيل عقار، طريقة تصنيعه وطريقة استخدامه
|